Nedal (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nedal, is a beta blocker presented as a tablet for oral use. It selectively blocks β1‑adrenergic receptors and also enhances nitric‑oxide release, helping to lower blood pressure and improve cardiac function in adults with hypertension or heart failure. It is indicated for the management of high blood pressure and for chronic heart failure, offering a once‑daily dosing option that supports patient adherence.

GNH USA supplies Nedal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

- Hypertension: lowers systolic and diastolic blood pressure, improving overall control in adults with primary hypertension. - Heart failure: enhances left ventricular ejection fraction and reduces symptoms in chronic heart failure patients. - Diabetes‑associated hypertension: provides effective blood pressure reduction with a favorable metabolic profile for patients with type 2 diabetes. - Elderly patients with hypertension: offers once‑daily dosing that supports adherence and reduces cardiovascular risk in older adults.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Dizziness - Fatigue - Nasal congestion - Bradycardia - Nausea

Serious or Rare Side Effects: - Severe bradycardia - Heart block - Acute heart failure exacerbation - Bronchospasm in asthmatic patients - Elevated liver enzymes - Allergic skin reactions

When prescribing Nebivolol, clinicians should consider several safety measures. - Blood pressure monitoring: check regularly during initiation and dose adjustments. - Heart rate monitoring: observe for excessive bradycardia. - Asthma or COPD: use with caution due to potential bronchospasm. - Renal impairment: dose adjustment may be required. - Drug interactions: review concomitant medications for beta‑blocker or CYP2D6 inhibitors. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Nebivolol can interact with various medicines; careful review is essential.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia. - Clonidine abrupt withdrawal: may cause rebound hypertension. - CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels. - Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect. - ACE inhibitors or ARBs: additive blood pressure lowering. - Tricyclic antidepressants: may increase risk of cardiac conduction effects. - NSAIDs: may reduce antihypertensive efficacy. - Antiplatelet agents: monitor for bleeding if combined with other antihypertensives.